Retro announces initial close of financing
The round values the company at $1.8 billion, led by 4P Capital, funding RTR242's clinical advancement and expansion of cell therapy, AI protein engineering, and manufacturing capabilities.
Latest Retro Biosciences News & Updates
See the latest news and media coverage for Retro. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of therapeutics targeting cellular aging
retro.bio- Headquarters
- Redwood City, United States
- Company type
- Private company
- Number of employees
- 90–200
Last updated
Latest news about Retro Biosciences (Retro)
In short: Retro announced the initial close of a $1.8 billion financing round and transitioned into a clinical-stage company with its first-in-human trial.
Company announcements
Retro achieves First In Human milestone
Retro becomes a clinical stage company after reaching the clinic in Q4. The organization thanks teams and anticipates 2026.
Retro Bio highlights collaboration with OpenAI on GPT-4b
The partnership focuses on using GPT-4b to engineer proteins that enhance stem cell reprogramming and accelerate their mission.
Retro Bio announces collaboration with MCRI
The partnership aims to develop preventative medicine by rejuvenating the blood system using a person's genetics to extend healthy lifespan by 10 years.
Media coverage
This method to reverse cellular aging is about to be tested in humans
A burgeoning field is launching its first clinical trial to find out whether dialing back cell development can safely refresh ...
This method to reverse cellular ageing is about to be tested in humans
A burgeoning field is launching its first clinical trial to find out whether dialling back cell development can safely refresh aged tissues and organs.
Retro Bio commences first-in-human trial
Autophagy-enhancing drug candidate enters Phase 1 trial as longevity focused biotech eyes Alzheimer's as a potential first indication.
Exclusive: Retro Hopes It Has Found A New Way To Combat Alzheimer's Disease
Almost three years ago, the world learned that OpenAI CEO Sam Altman had put a staggering $180 million into a longevity start-up called Retro Bio...
Never miss news about Retro
Track Retro and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Retro competitors & trending companies
Browse news for competitors to Retro and other trending companies.